Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines provide essential tools for the control of the COVID-19 pandemic. A number of technologies have been employed to develop SARS-CoV-2 vaccines, including the inactivated SARS-CoV-2 particles, mRNA to express viral spike protein, recombinant spike proteins, and viral vectors. Here, we report the use of the vaccinia virus Tiantan strain as a vector to express the SARS-CoV-2 spike protein. When it was used to inoculate mice, robust SARS-CoV-2 spike protein-specific antibody response and T-cell response were detected. Sera from the vaccinated mice showed strong neutralizing activity against the ancestral Wuhan SARS-CoV-2, the variants of concern (VOCs) B.1.351, B.1.617.2, and the emerging B.1.1.529 (omicron). This finding supports the possibility of developing a new type of SARS-CoV-2 vaccine using the vaccinia virus vector.
Keywords: COVID-19; SARS-CoV-2; spike protein; vaccine; vaccinia virus.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, Spike protein, vaccinia virus, 【초록키워드】 severe acute respiratory syndrome coronavirus 2, coronavirus, B.1.351, COVID-19 pandemic, Antibody Response, T-cell Response, variants of concern, B.1.617.2, SARS-CoV-2 vaccines, severe acute respiratory syndrome Coronavirus, variants, SARS-CoV-2 vaccine, Spike protein, Neutralizing activity, Viral, mice, mRNA, vector, sera, SARS-CoV-2 spike protein, Wuhan, VOCs, viral vectors, vaccinia virus, B.1.1.529, respiratory, inactivated, SARS-CoV-2 spike, Spike proteins, Support, viral spike protein, acute respiratory syndrome, acute respiratory syndrome coronavirus, recombinant spike proteins, Express, SARS-CoV-2 particles, robust, was used, develop, the SARS-CoV-2, 【제목키워드】 immunogenicity, vaccine candidate, acute respiratory syndrome,